Last reviewed · How we verify
Glioblastoma multiforme
Approved treatments
- Avastin · Washington University School of Medicine
- Bevacizumab · Roche
Bevacizumab binds VEGF and prevents interaction with endothelial cell receptors Flt-1 and KDR. - Avastin · Roche
Bevacizumab works by binding to VEGF-A, preventing it from promoting the growth of new blood vessels that feed tumors.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Glioblastoma multiforme patent landscape — cliff calendar, originator estates, attackable patents
- Glioblastoma multiforme treatment landscape brief
- Glioblastoma multiforme treatment updates RSS
Frequently asked questions about Glioblastoma multiforme
What drugs treat Glioblastoma multiforme?
Tracked treatments include Avastin, Bevacizumab.
What is the treatment for Glioblastoma multiforme?
Standard treatment for Glioblastoma multiforme includes Avastin, Bevacizumab. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Glioblastoma multiforme patent cliff · Glioblastoma multiforme CI report
- Treatment: Avastin · Washington University School of Medicine
- Treatment: Bevacizumab · Roche
- Treatment: Avastin · Roche
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing